On June 3, 2025, the Food and Drug Administration (FDA) sanctioned darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA has...
prostate-cancer-treatment
Prostate Cancer Chemotherapy
Introduction
Prostate cancer is one of the most common cancers in men worldwide. Although most are slow-growing and do not need aggressive treatment at first, advanced o...
prostate-cancer-treatment
Prostate Cancer Treatment
Prostate cancer is a leading type of cancer in men globally, especially men above the age of 50. Due to early diagnosis and treatment methods, survival rates have increased ...
prostate-cancer-treatment